General description
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1N3 is a ZooMAb® rabbit recombinant monoclonal antibody that detects IL-12B. It targets an epitope within 24 amino acids from the N-terminal half.
Immunogen
KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal half of human IL-12B.
Application
Quality Control Testing
Evaluated by Western Blotting with a recombinant fragment of human IL-12 p80.
Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected a recombinant fragment of human IL-12 p80.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected IL-12B in lysate from THP-1 cells treated with lipopolysaccharide ( (LPS; 1 ng/ml, 1 hour), but not in untreated cells.
Enzyme Immunoassay: A representative lot of this antibody detected IL-12 p80 protein in ELISA application.
Affinity Binding Assay: A representative lot of this antibody bound with IL-12B peptide with at least one hundred thousand-fold (100,000X) higher affinity than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Interleukin-12 subunit beta (UniProt: P29460; also known as Cytotoxic lymphocyte maturation factor 40 kDa subunit (CLMF p40), IL-12 subunit p40, NK cell stimulatory factor chain 2 (NKSF2)) is encoded by the IL12B (also known as NKSF2 ) gene (Gene ID: 3593) in human. Interleukin-12 subunit beta (IL12B), also known as IL-12p40, is a crucial component of the cytokines IL-12 and IL-23, which play significant roles in immune responses by promoting the differentiation of naive T cells into Th1 cells and enhancing interferon-gamma (IFN- ) production by natural killer (NK) and T cells. IL-12 is a disulfide-linked heterodimeric protein (p70), composed of two subunits, p35 and p40, which are encoded by two different genes. In addition, to its ability to covalently bind to p35 to form IL-12, p40 can bind to p19 to form IL-23, or can form a homodimer designated as IL-12 p80. Elevated levels of IL-12 p80 are correlated with macrophage recruitment and increased inflammation in asthma and respiratory viral infection models. IL12B is primarily expressed in activated macrophages and dendritic cells, secreted in response to pathogenic stimuli. Genetic variations in IL12B have been associated with autoimmune diseases such as inflammatory bowel disease (IBD) and psoriasis, highlighting its role in immune system dysregulation. Advances in understanding IL12B′s role in disease have shown that epigenetic regulation, such as targeted DNA methylation, can significantly alter its expression levels, suggesting potential therapeutic strategies. IL12B has been implicated in cancer, particularly colorectal cancer, where its modulation could enhance antitumor immune responses. Recent studies have explored the potential of IL12B as a therapeutic target in cancer immunotherapy. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Zundler, S. and Neurath MF., (2015), Cytokine Growth Factor Rev, 26(5), 559-568; Chen, H., et al., (2024) Structure, 32(10), 1640 1651.E5).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.